Soluble ST2 and galectin-3 in pediatric patients without heart failure

Jeffrey W. Meeusen; Jonathan N. Johnson; Amber Gray; Patricia Wendt; John L. Jefferies; Allan S. Jaffe; Leslie J. Donato; Amy K. Saenger

doi:10.1016/j.clinbiochem.2015.08.007

Soluble ST2 and galectin-3 in pediatric patients without heart failure

Jeffrey W. Meeusen, Jonathan N. Johnson, Amber Gray, Patricia Wendt, John L. Jefferies, Allan S. Jaffe, Leslie J. Donato, Amy K. Saenger

Research output: Contribution to journal › Article › peer-review

27 Scopus citations

Abstract

Objectives: Soluble ST2 (ST2) and galectin-3 (Gal3) are biomarkers of myocardial fibrosis and remodeling. This study provides a foundation for the use of ST2 and Gal3 in pediatric patients by assessing values of these biomarkers among children without heart failure. Design and methods: Sera from 240 children, 40 males and 40 females from each of three age groups, (2-6 years, 7-11 years, and 12-17 years) without heart failure were identified from residual clinical testing. Serum ST2 and Gal3 were measured by ELISA. Results: Serum ST2 increased with age among males, but not females. However, the difference was not statistically significant at the 95th or 97.5th percentiles. No relationship was found between serum Gal3 concentrations and age or gender. Central 95th percentiles (2.5th to 97.5th) were 9-50 ng/mL for ST2 and 7-33 ng/mL for Gal3. Conclusions: We have presented baseline, normative data for ST2 and Gal3 in children. This will allow for study of the utility of these biomarkers in children with heart disease.

Original language	English (US)
Pages (from-to)	1337-1340
Number of pages	4
Journal	Clinical Biochemistry
Volume	48
Issue number	18
DOIs	https://doi.org/10.1016/j.clinbiochem.2015.08.007
State	Published - Dec 1 2015

Keywords

Biomarkers
Cardiomyopathy
Natriuretic peptides
Reference range

ASJC Scopus subject areas

Clinical Biochemistry

Access to Document

10.1016/j.clinbiochem.2015.08.007

Cite this

@article{3a6a0434d0dc47d88d1e560391b8ae5d,

title = "Soluble ST2 and galectin-3 in pediatric patients without heart failure",

abstract = "Objectives: Soluble ST2 (ST2) and galectin-3 (Gal3) are biomarkers of myocardial fibrosis and remodeling. This study provides a foundation for the use of ST2 and Gal3 in pediatric patients by assessing values of these biomarkers among children without heart failure. Design and methods: Sera from 240 children, 40 males and 40 females from each of three age groups, (2-6 years, 7-11 years, and 12-17 years) without heart failure were identified from residual clinical testing. Serum ST2 and Gal3 were measured by ELISA. Results: Serum ST2 increased with age among males, but not females. However, the difference was not statistically significant at the 95th or 97.5th percentiles. No relationship was found between serum Gal3 concentrations and age or gender. Central 95th percentiles (2.5th to 97.5th) were 9-50 ng/mL for ST2 and 7-33 ng/mL for Gal3. Conclusions: We have presented baseline, normative data for ST2 and Gal3 in children. This will allow for study of the utility of these biomarkers in children with heart disease.",

keywords = "Biomarkers, Cardiomyopathy, Natriuretic peptides, Reference range",

author = "Meeusen, {Jeffrey W.} and Johnson, {Jonathan N.} and Amber Gray and Patricia Wendt and Jefferies, {John L.} and Jaffe, {Allan S.} and Donato, {Leslie J.} and Saenger, {Amy K.}",

note = "Publisher Copyright: {\textcopyright} 2015 The Canadian Society of Clinical Chemists.",

year = "2015",

month = dec,

day = "1",

doi = "10.1016/j.clinbiochem.2015.08.007",

language = "English (US)",

volume = "48",

pages = "1337--1340",

journal = "Clinical Biochemistry",

issn = "0009-9120",

publisher = "Elsevier Inc.",

number = "18",

}

TY - JOUR

T1 - Soluble ST2 and galectin-3 in pediatric patients without heart failure

AU - Meeusen, Jeffrey W.

AU - Johnson, Jonathan N.

AU - Gray, Amber

AU - Wendt, Patricia

AU - Jefferies, John L.

AU - Jaffe, Allan S.

AU - Donato, Leslie J.

AU - Saenger, Amy K.

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Objectives: Soluble ST2 (ST2) and galectin-3 (Gal3) are biomarkers of myocardial fibrosis and remodeling. This study provides a foundation for the use of ST2 and Gal3 in pediatric patients by assessing values of these biomarkers among children without heart failure. Design and methods: Sera from 240 children, 40 males and 40 females from each of three age groups, (2-6 years, 7-11 years, and 12-17 years) without heart failure were identified from residual clinical testing. Serum ST2 and Gal3 were measured by ELISA. Results: Serum ST2 increased with age among males, but not females. However, the difference was not statistically significant at the 95th or 97.5th percentiles. No relationship was found between serum Gal3 concentrations and age or gender. Central 95th percentiles (2.5th to 97.5th) were 9-50 ng/mL for ST2 and 7-33 ng/mL for Gal3. Conclusions: We have presented baseline, normative data for ST2 and Gal3 in children. This will allow for study of the utility of these biomarkers in children with heart disease.

AB - Objectives: Soluble ST2 (ST2) and galectin-3 (Gal3) are biomarkers of myocardial fibrosis and remodeling. This study provides a foundation for the use of ST2 and Gal3 in pediatric patients by assessing values of these biomarkers among children without heart failure. Design and methods: Sera from 240 children, 40 males and 40 females from each of three age groups, (2-6 years, 7-11 years, and 12-17 years) without heart failure were identified from residual clinical testing. Serum ST2 and Gal3 were measured by ELISA. Results: Serum ST2 increased with age among males, but not females. However, the difference was not statistically significant at the 95th or 97.5th percentiles. No relationship was found between serum Gal3 concentrations and age or gender. Central 95th percentiles (2.5th to 97.5th) were 9-50 ng/mL for ST2 and 7-33 ng/mL for Gal3. Conclusions: We have presented baseline, normative data for ST2 and Gal3 in children. This will allow for study of the utility of these biomarkers in children with heart disease.

KW - Biomarkers

KW - Cardiomyopathy

KW - Natriuretic peptides

KW - Reference range

UR - http://www.scopus.com/inward/record.url?scp=84949093186&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949093186&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2015.08.007

DO - 10.1016/j.clinbiochem.2015.08.007

M3 - Article

C2 - 26277636

AN - SCOPUS:84949093186

SN - 0009-9120

VL - 48

SP - 1337

EP - 1340

JO - Clinical Biochemistry

JF - Clinical Biochemistry

IS - 18

ER -

Soluble ST2 and galectin-3 in pediatric patients without heart failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this